Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders
NCT07311655 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-12-31
Summary
The trial aimed to evaluate the efficacy of an artificial intelligence-based system for diagnosing anxiety disorders. Specifically, it sought to determine whether the system's assessment validity is non-inferior to that of psychiatric specialists.
Conditions
- Anxiety Disorders
Sponsors & Collaborators
-
Shanghai Mental Health Center
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-02-01
- Primary Completion
- 2026-03-15
- Completion
- 2026-03-15
Countries
- China
Study Locations
More Related Trials
-
Tutorial of Clinical Trial Registration
NCT03481452 ·Status: UNKNOWN ·Phase: NA
-
Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research
NCT06155565 ·Status: NOT_YET_RECRUITING
-
Experimental Medication For the Treatment of Generalized Anxiety Disorder
NCT00097708 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness of Electronic Interventions on the Standardized Prescription Benzodiazepines and Z-drugs
NCT03724669 ·Status: COMPLETED ·Phase: NA
-
Evaluating a Personalized Trans-Diagnostic Group Therapy for Anxiety
NCT03457922 ·Status: COMPLETED
-
Trait Anxiety and Defensive Networks
NCT02682888 ·Status: COMPLETED ·Phase: NA
-
Acceptance-Based Treatment for Generalized Anxiety Disorder
NCT00073632 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
NCT00731120 ·Status: COMPLETED ·Phase: PHASE3
-
Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers
NCT02200003 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
NCT00108836 ·Status: COMPLETED ·Phase: PHASE2
-
Threat Reversal Abnormality in Patients With Anxiety Disorders
NCT06232369 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Duloxetine for the Treatment of Generalized Anxiety Disorder
NCT00803361 ·Status: COMPLETED ·Phase: PHASE3
-
Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)
NCT02579915 ·Status: COMPLETED ·Phase: NA
-
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
NCT00734071 ·Status: COMPLETED ·Phase: PHASE3
-
Attention Bias Modification for Transdiagnostic Anxiety
NCT02303691 ·Status: COMPLETED ·Phase: NA
-
Computer-Based Treatment for Social Anxiety Disorder
NCT03415022 ·Status: COMPLETED ·Phase: NA
-
The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers
NCT01826786 ·Status: COMPLETED ·Phase: PHASE1
-
Novel Anxiety Treatment
NCT03790696 ·Status: COMPLETED ·Phase: NA
-
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning
NCT00062517 ·Status: COMPLETED
-
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860 ·Status: COMPLETED ·Phase: PHASE3
-
The Relationship Between Social Anxiety and Anxious Thinking Styles
NCT05798078 ·Status: COMPLETED ·Phase: NA
-
Treatment of Hypochondriasis With CBT and/or SSRI
NCT00339079 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Open Trial of an ACT Skills Group and Mobile App for Worry
NCT03709433 ·Status: COMPLETED ·Phase: NA
-
Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety
NCT05683223 ·Status: RECRUITING ·Phase: NA
-
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
NCT00390533 ·Status: COMPLETED ·Phase: PHASE3